News
Arcutis provides update on phase IIa clinical trial for ARQ 252 Cream as a treatment for vitiligo.
Arcutis Biotherapeutics, Inc. announced its decision to terminate the recently initiated Phase IIa clinical trial evaluating ARQ 252, a topical small molecule inhibitor of Janus kinase type 1 (JAK1), as a potential treatment for vitiligo (ARQ-252-213). Arcutis’ decision is based on further analyses of the ARQ 252 drug formulation used in both this vitiligo study and the recently completed Phase IIb study evaluating ARQ-252 for the treatment of chronic hand eczema (ARQ-252-205).
As previously announced, the Phase IIb chronic hand eczema study did not meet its primary endpoint, with none of the ARQ-252 arms achieving statistical significance versus vehicle. Further analyses of that study pointed toward inadequate local drug delivery to the skin as a key driver of the lack of efficacy.
Condition: Vitiligo
Type: drug